Biological treatments for systemic lupus erythematosus

References

• Ruiz-Irastorza G, Khamashta MA, Castellino G, Hughes GR. Systemic lupus erythematosis. Lancet 2001;357:1027–32.
   Google Scholar
• Tsokos GC, Kovacs B, Sfikakis PP, Theocharis S, Vogelgesang S, Via CS. Defective antigen-presenting cell function in patients with systemic lupus erythematosis. Arthritis Rheum 1996;39:600–9.
   PubMedGoogle Scholar
• Ohtsuka K, Gray JD, Quismorio FPJ, Lee W, Horwitz DA. Cytokine mediated down-regulation of B cell activity in SLE: effects of interleukin-2 and transforming growth factor-beta. Lupus 1999;8:9 5–102.
   Google Scholar
• Rathmell JC, Fournier S, Weintraub BC, Allison JP, Goodnow CC. Repression of B7.2 on self-reactive B cells is essential to prevent proliferation and allow Fas-mediated deletion by CD4(+ ) T cells. J Exp Med 1998;188:65 1–9.
   Google Scholar
• Reiser H, Stadecker MJ. Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. N Engl J Med 1996;335:1369–77.
   PubMed Web of Science ®Google Scholar
• Dean GS, Tyrrell-Price J, Crawley E, Isenberg DA. Cytokines and systemic lupus erythematosus. Ann Rheum Dis 2000; 59:243–51.
   PubMed Web of Science ®Google Scholar
• Davas EM, Tsirogianni A, Kappou I, Karamitsos D, Economidou I, Dantis PC. Serum IL-6, TNF alpha, p55 srTNFalpha, p75srTNFalpha, srIL-2alpha levels and disease activity in systemic lupus erythematosis. Clin Rheumatol 1999;18:17–22.
   PubMedGoogle Scholar
• Jacob CO, McDevitt HO. Tumour necrosis factor-alpha in murine autoimmune "lupus" nephritis. Nature 1988;331: 356–8.
   PubMed Web of Science ®Google Scholar
• Hirohata S, Miyamoto T. Elevated levels of interleukin-6 in cerebro-spinal fluid from patients with systemic lupus erythematosis and central nervous system involvement. Arthritis Rheum 1990;33:644–9.
   PubMed Web of Science ®Google Scholar
• Gordon C, Richards N, Howie AJ, Richardson K, Michael J, Adu D, et al. Urinary IL-6: a marker for mesangial pro-liferative glomerulonephritis. Clin Exp Immunol 1991;86: 145–9.
   PubMed Web of Science ®Google Scholar
• Theofilopoulos AN, Koundouris S, Kono DH, Lawson BR. The role of IFN-gamma in systemic lupus erythematosus: a challenge to the Thl/Th2 paradigm in autoimmunity. Arthritis Res 2001;3:136–41.
   PubMedGoogle Scholar
• Seery JP. IFN-gamma transgenic mice: clues to the patho-genesis of systemic lupus erythematosus? Arthritis Res 2000; 2:437–40.
   PubMedGoogle Scholar
• Tokano Y, Morimoto S, Kaneko H, Amano H, Nozawa K, Takasaki Y, et al. Levels of IL-12 in the sera of patients with systemic lupus erythematosus (SLE)-relation to Thl- and Th2-derived cytokines. Clin Exp Immunol 1999;116:169–73.
   PubMed Web of Science ®Google Scholar
• Llorente L, Richard-Patin Y, Wijdenes J, Alcocer-Varela J, Maillot MC, Durand-Gasselin I, et al. Spontaneous produc-tion of interluekin-10 by B lymphocytes and monocytes in systemic lupus erythematosis. Eur Cytokine Netw 1993; 4:421–7.
   PubMed Web of Science ®Google Scholar
• Houssiau FA, Lefebvre C, Vanden Berghe M, Lambert M, Devogelaer JP, Renauld JC. Serum interleukin-10 titres in systemic lupus eryhtematosus reflect diease activity. Lupus 1995;4:39 3–5.
   PubMedGoogle Scholar
• Hase K, Tani K, Shimizu T, Ohmoto Y, Matsushima K, Sone S. Increased CCR4 expression in active systemic lupus erythematosus. J Leukoc Biol 2001;70:749–55.
   PubMedGoogle Scholar
• Llorente L, Zou W, Levy Y, Richard-Patin Y, Wijdenes J, Alcocer-Varela J, et al. Role of interleukin 10 in B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 1995;181: 839–44.
   Google Scholar
• Buelens C, Willems F, Delvaux A, Pierard G, Delville JP, Velu T, et al. Interleukin-10 differentially regulates B7-1(CD80) and B7-2(CD86) expression on human peripheral blood dendritic cells. Eur J Immunol 1995;25:266 8–72.
   Google Scholar
• Lauwerys BR, Garot N, Renauld JC, Houssiau FA. Interleukin-10 blockade corrects impaired in vitro cellular immune responses of systemic lupus erythematosus patients. Arthritis Rheum 2000;43:1976–81.
   PubMed Web of Science ®Google Scholar
• Liu TF, Jones BM. Impaired production of IL-12 in systemic lupus erythematosus. II: IL-12 production in vitro is correlated negatively with serum 1L-10, positively with serum IFN-gamma and negatively with disease activity in SLE. Cytokine 1998;10:14 8–53.
   Google Scholar
• Liu TF, Jones BM. Impaired production of IL-12 in systemic lupus erythematosus. I: Excessive production of 1L-10 sup-presses production of 1L-12 by monocytes. Cytokine 1998; 10:140–7.
   Google Scholar
• MM DJ, Cho ML, Cho CS, Min SY, Kim WU, Yang SY, et al. Decreased production of interleukin-12 and interferon-gamma is associated with renal involvement in systemic lupus erythematosus. Scand J Rheumatol 2001;30:15 9–63.
   Google Scholar
• Tyrrell-Price J, Lydyard PM, Isenberg DA. The effect of interleukin-10 and of interleukin-12 on the in vitro production of anti-double-stranded DNA antibodies from patients with systemic lupus erythematosus. Clin Exp Immunol 2001;124: 118–25.
   Google Scholar
• Emilie D, Mariette X. Interleukin 10: a new therapeutic target in systemic lupus erythematosus? Joint Bone Spine 2001;68: 4–5.
   PubMedGoogle Scholar
• Segal R, Dayan M, Zinger H, Mozes E. Suppression of experimental systemic lupus erythematosus (SLE) in mice via TNF inhibition by an anti-TNFalpha monoclonal antibody and by pentoxiphylline. Lupus 2001;10:23–31.
   PubMed Web of Science ®Google Scholar
• Finck BK, Chan B, Wofsy D. Interleukin 6 promotes murine lupus in NZB/NZW Fl mice. J Clin Invest 1994;94: 585–91.
   Google Scholar
• Ishida H, Muchamuel T, Sakaguchi S, Andrade S, Menon S, Howard M. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W Fl mice. J Exp Med 1994;179(1):305–b0.
   Google Scholar
• Prud'homme GJ, Lawson BR, Theofilopoulos AN. Anticy-tokine gene therapy of autoimmune diseases. Expert Opin Biol Ther 2001;1: 359–73.
   Google Scholar
• Wofsy D, Seaman WE. Reversal of advanced murine lupus in NZB/NZW Fl mice by treatment with monoclonal antibody to L3T4. J Immunol 1987;138:3247–53.
   PubMed Web of Science ®Google Scholar
• Harper JM, Cook A. Beneficial effects of non-depleting anti-CD4 in MRL/Mp-lpr/lpr mice with active systemic lupus erythematosus and microscopic angiitis. Autoimmunity 2001; 33:245–51.
   PubMed Web of Science ®Google Scholar
• Brink I, Thiele B, Burmester GR, Trebelijahr G, Emmrich F, Hiepe F. Effects of anti-CD4 antibodies on the release of IL-6 and TNF-alpha in whole blood samples from patients iwth systemic lupus erythematosus. Lupus 1999;8:723–30.
   PubMedGoogle Scholar
• Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4 Ig. Science 1994;265: 1225–7.
   Google Scholar
• Mohan C, Shi Y, Laman JD, Datta SK. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 1995;154:1470–80.
   PubMed Web of Science ®Google Scholar
• Daikh DI, Finck BK, Linsley PS, Hollenbaugh D, Wofsy D. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 constimulation pathways. J Immunol 1997;159:310 4–8.
   Google Scholar
• Wang X, Huang W, Mihara M, Sinha J, Davidson A. Mechanism of action of combined short-term CTLA4Ig and anti-CD40 ligand in murine systemic lupus erythematosus. J Immunol 2002;168: 2046–53.
   Google Scholar
• Llorente L, Richaud-Patin Y, Garcia-Padilla C, Claret E, Jakez-Ocampo J, Cardiel MH, et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody adminis-tration in systemic lupus erythematosus. Arthritis Rheum 2000;43:179 0–800.
   Google Scholar
• Furie RA, C.ash JM, Cronin ME, Katz RS, Weisman MH, Aranow C, et al. Treatment of systemic lupus erythematosus with UP 394. J Rheumatol 2001;28:257–65.
   PubMed Web of Science ®Google Scholar
• Leandro M, Ehrenstein MR, Cambridge G, Edwards JC, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002 (in press).
   Google Scholar